文献速递类风湿关节炎

托珠单抗联合甲氨蝶呤治疗类风湿关节炎:甲氨蝶呤减量与非减量的随机双盲试验

Tapering versus steady-state methotrexate in combination with tocilizumab for rheumatoid arthritis: a randomized, double-blind trial.
PubMed 文献 · Rheumatology (Oxford) · 2018-01-01

这项随机双盲非劣效试验纳入对甲氨蝶呤反应不足的重度活动性类风湿关节炎患者,起始接受托珠单抗联合甲氨蝶呤治疗。第24周达到EULAR良好/中度缓解者随机分为甲氨蝶呤减量组或维持组,继续开放标签托珠单抗。结果显示减量组维持EULAR良好/中度缓解的比例非劣于维持组,且未发现意外安全性信号。

要点

  • 甲氨蝶呤减量组第24至60周维持EULAR良好/中度缓解的比例为76.5%,维持组为65.4%(P=0.036)。
  • 因95%CI下限>0.9,尽管招募不足提前终止,预设非劣效标准仍满足。
  • 两组均未发现意外的托珠单抗安全性信号,治疗总体耐受良好。

核心结论

  • 在托珠单抗联合甲氨蝶呤治疗类风湿关节炎患者中,甲氨蝶呤减量在维持EULAR良好/中度缓解方面非劣于持续稳定剂量甲氨蝶呤。

研究设计与样本

  • 随机、安慰剂对照、双盲非劣效研究,纳入DAS28>5.1的重度活动性RA患者,起始开放标签托珠单抗(8 mg/kg静脉每4周)联合开放标签甲氨蝶呤。
  • 第24周达到EULAR良好/中度缓解者随机分为双盲甲氨蝶呤减量组或维持组,两组继续开放标签托珠单抗,主要分析第24至60周维持EULAR良好/中度缓解的比例。
  • 研究因招募低提前终止;第0周开放标签阶段入组427例,第24周272例(64.4%)随机,每组136例(36%退出或不符合条件)。

主要发现

  • 第24周时,45.0%患者达到DAS28≤3.2,33.5%达到缓解(DAS28<2.6),64.2%患者DAS28变化≥1.2。
  • 随机后第24至60周,甲氨蝶呤减量组维持EULAR良好/中度缓解的比例显著高于稳定甲氨蝶呤组(76.5% vs 65.4%;P=0.036)。
  • 因95%CI下限>0.9,尽管招募减少,预设非劣效标准仍满足。
  • 安全性分析未发现意外的托珠单抗安全性信号。

关键数值与推荐

  • 非劣效标准:维持EULAR良好/中度缓解比例差异的95%CI下限>0.9。
  • 甲氨蝶呤减量组维持EULAR良好/中度缓解比例为76.5%,稳定甲氨蝶呤组为65.4%(P=0.036)。

临床怎么用

  • 对托珠单抗联合甲氨蝶呤治疗达到EULAR良好/中度缓解的RA患者,可考虑减量甲氨蝶呤而不影响疗效维持。
  • 减量甲氨蝶呤未增加意外安全性信号,但需在临床监测下进行。

局限性

  • 研究因招募低提前终止,可能影响统计效能和结果外推。
  • 随机化时36%患者退出或不符合条件,可能存在选择偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To explore whether tocilizumab + tapering MTX has comparable efficacy and safety vs tocilizumab + stable MTX in adult RA patients with inadequate response to MTX. METHODS: This randomized, placebo-controlled non-inferiority study involved patients with severe active RA [28-joint DAS (DAS28) >5.1] who had initiated tocilizumab + MTX at the study start. Patients received open-label tocilizumab (8 mg/kg i.v. every 4 weeks) and open-label MTX. At week 24, patients achieving good/moderate EULAR response were randomized to group A (double-blind MTX taper) or group B (double-blind MTX maintenance); both arms continued open-label tocilizumab. Primary analysis was the proportion of patients maintaining good/moderate EULAR response from week 24 to 60. RESULTS: The study stopped early due to low recruitment, although the predetermined non-inferiority criteria were still met; 427 patients were enrolled to the open-label phase at week 0. At week 24, EULAR good/moderate response was achieved in 272 individuals (64.4%) who were randomized, 136 in each arm (36% withdrew/were not eligible). Additionally, 45.0% achieved DAS28 ⩽3.2, 33.5% achieved remission (DAS28 <2.6) and 64.2% had a DAS28 change ⩾1.2. After week 24 randomization, the proportion of patients maintaining good/moderate EULAR response to week 60 was significantly greater for MTX taper vs stable MTX (76.5 vs 65.4%; P = 0.036), and since the lower limit of the 95% CI was >0.9, the pre-determined criteria for non-inferiority was fulfilled despite reduced recruitment. Safety analysis revealed no unexpected tocilizumab safety signals. CONCLUSIONS: Tapering MTX in patients with RA receiving tocilizumab was non-inferior to continuing stable MTX in maintaining a good/moderate EULAR response. There were no unexpected safety signals; tocilizumab and MTX therapy was generally well tolerated in both groups. Trial registration number: EudraCT 2011-005260-20.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Edwards CJ, Östör AJK, Naisbett-Groet B, et al. Tapering versus steady-state methotrexate in combination with tocilizumab for rheumatoid arthritis: a randomized, double-blind trial. Rheumatology (Oxford). 2018. PMID: 29155973. doi:10.1093/rheumatology/kex358

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。